文献速递肿瘤 PET/CT核素与放射性配体治疗

双相对比增强[18F]PSMA-1007 PET/CT显像改善前列腺癌局部复发检出

Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer.
PubMed 文献 · EJNMMI Res · 2025-05-30

这项单中心回顾性研究纳入24例生化复发的前列腺癌患者,评估双相对比增强[18F]PSMA-1007 PET/CT对术后前列腺床局部复发的检出效果。晚期显像中局部复发灶的SUVmax和SUVmean中位数分别升高26%和5%,TBR中位数升高185%,动力学指标变化均有统计学意义。在预选患者中,该优化采集方案使67%的患者诊断效能得到改善。

要点

  • 双相对比增强[18F]PSMA-1007 PET/CT可提高术后前列腺床局部复发的检出信心。
  • 晚期显像中局部复发灶SUVmax和SUVmean中位数分别升高26%和5%,TBR中位数升高185%。
  • 7例(29%)患者由PSMA-RADS 3A升级为5,另9例(38%)经尿道对比剂移位定性评估后升级为5。

核心结论

  • 在预选患者前提下,双相对比增强[18F]PSMA-1007 PET/CT优化采集方案改善了67%预选患者的局部前列腺癌复发诊断效能。
  • 作者认为该采集方案要求对患者进行良好平衡的预选。

研究设计与样本

  • 单中心回顾性研究,纳入24例生化复发的前列腺癌男性患者,复发时平均PSA水平为0.96 ng/ml。

主要发现

  • 双相对比增强[18F]PSMA-1007 PET/CT判定局部复发存在,其中22例经2年随访后的复合参考标准最终验证。
  • 注射[18F]PSMA-1007(平均注射活度240 MBq(±29))后平均105(±19)分钟采集全身对比增强PET/CT数据,平均140分钟(±10)采集盆腔低剂量CT晚期PET/CT。
  • 晚期显像中局部复发灶SUVmax和SUVmean中位数分别升高26%和5%,相对于闭孔内肌的TBR中位数升高185%。
  • 病灶SUV指标和TBR的动态变化有统计学意义(P值<0.001-0.019)。
  • 延迟[18F]PSMA-1007 PET/CT回顾性阅片使7例(29%)疑似局部复发患者从先前PSMA-RADS 3A升级为PSMA-RADS 5;其余患者中,尿道对比剂移位的定性评估使另外9例(38%)升级为PSMA-RADS 5。

关键数值与推荐

  • 局部复发存在以双相对比增强[18F]PSMA-1007 PET/CT判定一致为准,其中22例经2年随访复合参考标准验证。
  • PSMA-RADS分级升级:7例(29%)从3A升至5;另9例(38%)经尿道对比剂移位定性评估后升至5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The implementation of PSMA imaging in prostate cancer (PC) management has significantly improved the medical care of patients owing to its clinical impact, particularly with respect to biochemical recurrence. However, there is still an unmet clinical need regarding the correct discrimination of equivocal, centrally located, focal [18F]PSMA-1007 uptake without any CT-morphological findings in the postsurgical prostate bed. The aim of this monocentric, retrospective study was to investigate the efficacy of a biphasic, contrast-enhanced [18F]PSMA-1007 acquisition protocol. RESULTS: This study investigated a total of 24 biologically male patients with BCR, with a mean PSA level of 0.96 ng/ml at the time of recurrence. The presence of local relapse was regarded as consistent by biphasic, contrast-enhanced [18F]PSMA-1007 PET/CT scans, of which 22 cases were finally validated through the composite reference standard after a 2-years follow-up. The acquisition of whole-body, contrast-enhanced PET/CT imaging data was performed after a mean of 105 (± 19) minutes, whereas late-phase PET/CT imaging of the pelvis with low-dose CT was conducted after 140 min (± 10) on average following the intravenous application of [18F]PSMA-1007 (injected mean activity of 240 MBq (± 29)). The median SUVmax and SUVmean values of local relapse increased by 26% and 5%, respectively, in late-phase images. Moreover, median TBR with respect to the obturator internus muscle seemed to benefit the most from late-phase imaging, with an increase of 185%. The dynamics of the SUV metrics and TBR in lesions were statistically significant (P value < 0.001-0.019). Moreover, the retrospective reading of delayed [18F]PSMA-1007 PET/CT imaging provided an upgrade of the reporting for suspected local PC relapse from a previous PSMA-RADS 3A to a later PSMA-RADS 5 in seven patients (29%), unless the impact of contrast agent in the urethra would also be considered equally important. For the remaining patients, the qualitative evaluation of contrast agent displacement in the urethra was necessary for a final clinical decision that provided the upgrading of the reporting to PSMA RADS 5 for an additional nine patients (38%). CONCLUSIONS: Given the aforementioned, highly specific unmet clinical need for a relatively small ratio of patients with prostate cancer undergoing PSMA imaging, our proposed acquisition protocol mandates a well-balanced preselection of patients. Under this premise, the study results demonstrated that the optimized acquisition protocol with biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging improved the diagnostic performance for the detection of local PC recurrence in 67% of preselected patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mamlins E, Novruzov E, Watabe T, et al. Biphasic contrast-enhanced [18F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer. EJNMMI Res. 2025. PMID: 40445472. doi:10.1186/s13550-025-01252-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。